Charles River Laboratories (CRL) Tops Q2 EPS by 5c, beats revenue, offers guidance

Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $2.69, $0.05 better than the analyst estimate of $2.64. Revenue for the quarter came in at $1.06 billion versus the consensus estimate of $1.05 billion.

GUIDANCE:

Charles River Laboratories sees FY2023 EPS of $10.30-$10.90.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
• SpaceX receives Baa1 rating from Moody's with stable outlook
• SanDisk and Micron surge as Apple confirms memory price pass-through